Profile: Corixa Corporation is a biopharmaceutical company. We develop oncology and immunology products to manage human diseases. We are accredited with FDA approved Bexxar for the treatment of patients with CD20 positive, follicular, NHL, with & without transformation, whose disease is refractory to rituximab. We focus on immunotherapeutic products and a broad technology platform, that enables the fully integrated vaccine design on a standalone basis.